The role of inflammatory markers in the formation of subclinical atherosclerosis.

Abstract

The proposed 2018 definition of clinical conditions in cardiology, which can serve as a manifestation of subclinical atherosclerosis, including asymptomatic patients at risk for coronary heart disease, atypical course, changing the development of acute coronary syndrome, long preclinical period against the background of confirmed coronary atherosclerosis can cause some changes in diagnostic and treatment strategy according to the latest European guidelines. The aim of the study. To investigate the influence of Pregnancy-Associated Plasma Protein A (PAPP-A) and C-Reactive Protein (CRP) levels on the development of subclinical atherosclerosis. Key parameters assessed include the rate of change in carotid intima-media thickness (CIM), total ejection fraction, end-systolic volume, total cholesterol and exercise tolerance. Additionally, a comparison was made between the initial biomarker levels and changes observed in the treatment group (n=23) receiving statins and metabolic therapy (trimetazidine and magnesium B6).